Exact Sciences Corporation (EXAS)
Automate Your Wheel Strategy on EXAS
With Tiblio's Option Bot, you can configure your own wheel strategy including EXAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXAS
- Rev/Share 15.5634
- Book/Share 13.0725
- PB 4.8679
- Debt/Equity 1.0211
- CurrentRatio 2.889
- ROIC -0.1883
- MktCap 12047321565.0
- FreeCF/Share 0.8979
- PFCF 71.0262
- PE -11.9583
- Debt/Assets 0.4349
- DivYield 0
- ROE -0.3837
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EXAS | Mizuho | -- | Outperform | -- | $60 | April 10, 2025 |
| Initiation | EXAS | RBC Capital Mkts | -- | Sector Perform | -- | $52 | March 13, 2025 |
| Initiation | EXAS | Barclays | -- | Overweight | -- | $70 | Jan. 23, 2025 |
| Initiation | EXAS | Wells Fargo | -- | Overweight | -- | $75 | Aug. 28, 2024 |
News
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
5 Growth Stocks to Strengthen Your Portfolio in Q4 After a Fabulous Q3
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
After a stellar Q3 for Wall Street, five growth picks - MU, WDAY, EXAS, EVR, and CDE - stand out with rising earnings estimates.
Read More
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Read More
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggesting a short-term bullish trend.
Read More
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Healthmine and Exact Sciences partner to increase colorectal cancer screening rates through at-home testing and health plan incentives.
Read More
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Read More
Should You Continue to Hold EXAS Stock in Your Portfolio?
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Read More
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
Published: August 22, 2025 by: Business Wire
Sentiment: Neutral
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
Read More
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Read More
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Top 3 Health Care Stocks That Are Preparing To Pump This Month
Published: August 11, 2025 by: Benzinga
Sentiment: Positive
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Read More
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Published: August 07, 2025 by: Benzinga
Sentiment: Positive
Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.
Read More
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more attractive to value investors?
Read More
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Read More
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Exact Sciences Schedules Second Quarter 2025 Earnings Call
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: W.
Read More
QGEN or EXAS: Which Is the Better Value Stock Right Now?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
What Makes Exact Sciences (EXAS) a New Buy Stock
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Read More
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®.
Read More
Exact Sciences Earns 2025 Great Place To Work® Certification™
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and le.
Read More
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Positive
Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose challenges, but Exact's first-mover advantage and new product launches offer potential for continued revenue growth.
Read More
About Exact Sciences Corporation (EXAS)
- IPO Date 2001-02-01
- Website https://www.exactsciences.com
- Industry Medical - Diagnostics & Research
- CEO Kevin T. Conroy
- Employees 6900